Home/Pipeline/AIM Platform (Lead Program)

AIM Platform (Lead Program)

Type 1 Diabetes

Phase 1Active

Key Facts

Indication

Type 1 Diabetes

Phase

Phase 1

Status

Active

Company

Phaim Pharma

About Phaim Pharma

Phaim Pharma is a clinical-stage biotech pioneering Antigenic Immune Modulation (AIM), a platform designed to reset the immune system to cure or halt autoimmune diseases. Its lead program targets Type 1 Diabetes (T1D), a condition with significant unmet need and no current disease-modifying therapies. Backed by a leadership team with deep expertise in immunology and drug development, Phaim is positioning itself to address a large and growing autoimmune market. The company is privately held, pre-revenue, and has secured non-dilutive funding and awards to advance its research.

View full company profile

Therapeutic Areas

Autoimmune Diseases Type 1 Diabetes Psoriasis Rheumatoid Arthritis Multiple Sclerosis

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active